Top 10 Stocks Under $10 That Could Triple

6. Bicycle Therapeutics plc (NASDAQ:BCYC)

Share Price: $7.16

Average Price Target Upside Potential According to Analysts: 256.15%

Number of Hedge Fund Holders: 26

Bicycle Therapeutics plc (NASDAQ:BCYC) is one of the top stocks under $10 that could triple. On August 11, RBC Capital increased its price target on Bicycle Therapeutics plc (NASDAQ:BCYC) from $25 to $27 and kept an Outperform rating after the company reported its Q2 2025 results.

The research firm pointed out that the update on the Duravelo-2 dose selection is still expected in the fourth quarter of 2025. However, updates on Duravelo-1 are now expected in 2026, later than initially planned.

RBC Capital also highlighted Bicycle Therapeutics plc’s (NASDAQ:BCYC) efforts to reduce costs, mainly through a workforce reduction. This will help the company extend its cash runway into 2028. The company is focused on advancing its clinical programs through key milestones.

The firm is also confident that Bicycle Therapeutics plc’s (NASDAQ:BCYC) zelenectide could offer competitive efficacy compared to Padcev with an improved safety profile. RBC Capital indicated that the market is currently undervaluing the $2 billion oncology opportunity for zelenectide.

Previously, on August 8, Needham had also reiterated a Buy rating on Bicycle Therapeutics plc (NASDAQ:BCYC) with a $28 price target following the company’s Q2 2025 results.

Needham’s Buy rating reflects the company’s new plan to reduce costs by 30%. This move provides a stable foundation for Bicycle Therapeutics plc’s (NASDAQ:BCYC) ongoing projects and improves investor confidence about the company’s future.

Overall, analysts are bullish on Bicycle Therapeutics plc (NASDAQ:BCYC). The 12-month median price target of $25.50 set by analysts suggests a potential upside of 256% from the current stock price.

Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage pharmaceutical company focused on developing a novel class of medicines, called Bicycle molecules, for diseases that are underserved by existing therapeutics, especially solid tumor cancers.